Mirati Therapeutics (Mirati Therapeutics) Total Inventories : $20.16 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Total Inventories?

Mirati Therapeutics's total inventories for the quarter that ended in Sep. 2023 was $20.16 Mil. Mirati Therapeutics's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Sep. 2023 was $14.40 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Mirati Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $11.61.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Mirati Therapeutics's Days Inventory for the three months ended in Sep. 2023 was 778.90.

Inventory Turnover measures how fast the company turns over its inventory within a year. Mirati Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2023 was 0.12.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Mirati Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.88.

Mirati Therapeutics Total Inventories Historical Data

The historical data trend for Mirati Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Total Inventories Chart

Mirati Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

3.02

Mirati Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Inventories	Get a 7-Day Free Trial															-	3.02	3.85	8.64	20.16

Mirati Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Mirati Therapeutics (NAS:MRTX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Mirati Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is

	Net-Net Working Capital Per Share (Q: Sep. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(976.434	+	0.75 * 14.651	+	0.5 * 20.156	-	183.243
-	0	-	0)	/	70.1113
=	11.61

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Mirati Therapeutics's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	14.4	/	1.687	*	365 / 4
	=	778.90

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Mirati Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2023 )	/	Average Total Inventories (Q: Sep. 2023 )
	=	1.687	/	14.4
	=	0.12

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mirati Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	14.4	/	16.4
	=	0.88

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Mirati Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirati Therapeutics (Mirati Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

26M:Germany

Address

3545 Cray Court, San Diego, CA, USA, 92121

Website

https://www.mirati.com

Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Executives

Jamie Christensen	officer: Sr. Vice President, Chief Scie	C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey	officer: EVP, Chief Commercial Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey	officer: Interim CFO	3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty	officer: Chief Legal Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer	officer: CFO	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121